Delaware | 26-2940963 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
10005 Muirlands Blvd. Suite G, Irvine, California | 92618 | |
(Address of Principal Executive Offices) | (Zip Code) |
PART I – FINANCIAL INFORMATION
|
||||
|
||||
1
|
||||
2
|
||||
Condensed Consolidated Statements of Operations for the six months ended July 2, 2016 and July 4, 2015 (Unaudited) | 3 | |||
4
|
||||
5
|
||||
6
|
||||
13
|
||||
17
|
||||
18
|
||||
|
||||
19
|
||||
19
|
||||
27
|
||||
27
|
||||
27
|
||||
27
|
||||
28
|
||||
|
July 2, 2016
|
January 2, 2016
|
|||||||
(Unaudited)
|
||||||||
Assets
|
||||||||
Current assets
|
||||||||
Cash
|
$ | 3,370,219 | $ | 5,549,672 | ||||
Trade receivables, net of allowances of $397,000 and $367,000, respectively
|
6,793,779 | 2,450,591 | ||||||
Inventories
|
4,524,803 | 8,173,799 | ||||||
Prepaid expenses and other assets
|
465,711 | 373,567 | ||||||
Total current assets
|
15,154,512 | 16,547,629 | ||||||
Leasehold improvements and equipment, net
|
1,860,476 | 1,788,645 | ||||||
Deposits
|
233,570 | 58,883 | ||||||
Intangible assets, net
|
510,637 | 354,052 | ||||||
Longterm investment
|
20,318 | - | ||||||
Total assets
|
$ | 17,779,513 | $ | 18,749,209 | ||||
Liabilities and stockholders' equity
|
||||||||
Current liabilities
|
||||||||
Accounts payable
|
$ | 2,331,376 | $ | 6,223,958 | ||||
Accrued expenses
|
1,937,427 | 1,302,865 | ||||||
Current maturities of loan payable
|
- | 1,528,578 | ||||||
Current maturities of capital lease obligations
|
218,126 | 219,689 | ||||||
Customer deposits and other
|
262,852 | 272,002 | ||||||
Deferred rent, current
|
38,350 | 39,529 | ||||||
Total current liabilities
|
4,788,131 | 9,586,621 | ||||||
Loan payable, less current maturities, net
|
- | 3,345,335 | ||||||
Capital lease obligations, less current maturities
|
337,903 | 444,589 | ||||||
Deferred rent, less current
|
205,826 | 97,990 | ||||||
Total liabilities
|
5,331,860 | 13,474,535 | ||||||
Commitments and contingencies
|
||||||||
Stockholders' equity
|
||||||||
Common stock, $.001 par value; authorized 50,000,000 shares; issued and outstanding
|
||||||||
July 2, 2016 37,489,914 and January 2, 2016 36,003,589 shares
|
37,490 | 36,004 | ||||||
Additional paid-in capital
|
54,532,594 | 47,534,059 | ||||||
Accumulated deficit
|
(42,122,431 | ) | (42,295,389 | ) | ||||
Total stockholders' equity
|
12,447,653 | 5,274,674 | ||||||
Total liabilities and stockholders' equity
|
$ | 17,779,513 | $ | 18,749,209 |
July 2, 2016
|
July 4, 2015
|
|||||||
Sales, net
|
$ | 8,829,579 | $ | 6,101,380 | ||||
Cost of sales
|
4,702,132 | 3,630,688 | ||||||
Gross profit
|
4,127,447 | 2,470,692 | ||||||
Operating expenses:
|
||||||||
Sales and marketing
|
698,031 | 639,748 | ||||||
Research and development
|
751,726 | 175,410 | ||||||
General and administrative
|
2,306,559 | 1,839,594 | ||||||
Operating expenses
|
3,756,316 | 2,654,752 | ||||||
Operating income (loss)
|
371,131 | (184,060 | ) | |||||
Nonoperating income (expense):
|
||||||||
Interest income
|
638 | 645 | ||||||
Interest expense
|
(145,424 | ) | (131,777 | ) | ||||
Loss on debt extinguishment
|
(313,099 | ) | - | |||||
Nonoperating expenses
|
(457,885 | ) | (131,132 | ) | ||||
Loss before taxes
|
(86,754 | ) | (315,192 | ) | ||||
Provision for taxes
|
4,087 | - | ||||||
Net loss
|
$ | (82,667 | ) | $ | (315,192 | ) | ||
Basic and diluted loss per common share
|
$ | (0.00 | ) | $ | (0.01 | ) | ||
Basic and diluted weighted average common shares outstanding
|
36,990,032 | 35,803,298 |
July 2, 2016
|
July 4, 2015
|
|||||||
Sales, net
|
$ | 16,161,524 | $ | 11,362,351 | ||||
Cost of sales
|
8,582,658 | 6,964,035 | ||||||
Gross profit
|
7,578,866 | 4,398,316 | ||||||
Operating expenses:
|
||||||||
Sales and marketing
|
1,242,753 | 1,225,525 | ||||||
Research and development
|
1,215,798 | 296,505 | ||||||
General and administrative
|
4,295,118 | 3,966,430 | ||||||
Operating expenses
|
6,753,669 | 5,488,460 | ||||||
Operating income (loss)
|
825,197 | (1,090,144 | ) | |||||
Nonoperating income (expense):
|
||||||||
Interest income
|
1,432 | 1,363 | ||||||
Interest expense
|
(333,919 | ) | (251,926 | ) | ||||
Loss on debt extinguishment
|
(313,099 | ) | - | |||||
Nonoperating expenses
|
(645,586 | ) | (250,563 | ) | ||||
Income (loss) before taxes
|
179,611 | (1,340,707 | ) | |||||
Provision for taxes
|
(6,653 | ) | - | |||||
Net income (loss)
|
$ | 172,958 | $ | (1,340,707 | ) | |||
Basic earnings (loss) per common share
|
$ | 0.00 | $ | (0.04 | ) | |||
Diluted earnings (loss) per common share
|
$ | 0.00 | $ | (0.04 | ) | |||
Basic weighted average common shares outstanding
|
36,702,037 | 35,768,082 | ||||||
Diluted weighted average common shares outstanding
|
37,470,666 | 35,768,082 |
Common Stock
|
Additional
|
Accumulated
|
Total Stockholders'
|
|||||||||||||||||
Shares
|
Amount
|
Paid-in Capital
|
Deficit
|
Equity
|
||||||||||||||||
Balance, January 2, 2016
|
36,003,589 | $ | 36,004 | $ | 47,534,059 | $ | (42,295,389 | ) | $ | 5,274,674 | ||||||||||
Issuance of common stock, net of
|
128,205 | 128 | 479,872 | - | 480,000 | |||||||||||||||
offering costs of $20,000
|
||||||||||||||||||||
Exercise of stock options
|
47,055 | 47 | 93,825 | - | 93,872 | |||||||||||||||
Share-based compensation
|
- | - | 324,035 | - | 324,035 | |||||||||||||||
Vested restricted stock
|
2,000 | 2 | (2 | ) | - | - | ||||||||||||||
Net income
|
- | - | - | 255,625 | 255,625 | |||||||||||||||
Balance, April 2, 2016
|
36,180,849 | $ | 36,181 | $ | 48,431,789 | $ | (42,039,764 | ) | $ | 6,428,206 | ||||||||||
1 for 3 reverse stock split, isssuance
|
||||||||||||||||||||
due to fractional shares round up
|
1,632 | 2 | (2 | ) | - | - | ||||||||||||||
Issuance of common stock, net of
|
1,117,022 | 1,117 | 5,238,883 | - | 5,240,000 | |||||||||||||||
offering costs of $10,000
|
||||||||||||||||||||
Exercise of stock options
|
185,081 | 185 | 528,327 | - | 528,512 | |||||||||||||||
Share-based compensation
|
- | - | 333,602 | - | 333,602 | |||||||||||||||
Vested restricted stock
|
5,330 | 5 | (5 | ) | - | - | ||||||||||||||
Net loss
|
- | - | - | (82,667 | ) | (82,667 | ) | |||||||||||||
Balance, July 2, 2016
|
37,489,914 | $ | 37,490 | $ | 54,532,594 | $ | (42,122,431 | ) | $ | 12,447,653 |
July 2, 2016
|
July 4, 2015
|
|||||||
Cash Flows From Operating Activities
|
||||||||
Net income (loss)
|
$ | 172,958 | $ | (1,340,707 | ) | |||
Adjustments to reconcile net income (loss) to net cash
|
||||||||
used in operating activities:
|
||||||||
Depreciation of leasehold improvements and equipment
|
159,370 | 137,279 | ||||||
Amortization of intangibles
|
38,415 | 20,541 | ||||||
Share-based compensation expense
|
657,637 | 1,223,177 | ||||||
Allowance for doubtful trade receivables
|
29,649 | 3,365 | ||||||
Loss from disposal of equipment
|
- | 18,226 | ||||||
Non-cash loss on debt extinguishment
|
32,007 | - | ||||||
Non-cash financing costs
|
94,080 | 92,143 | ||||||
Changes in operating assets and liabilities:
|
||||||||
Trade receivables
|
(4,372,837 | ) | (1,195,891 | ) | ||||
Inventories
|
3,628,678 | 645,308 | ||||||
Prepaid expenses and other assets
|
(266,831 | ) | (134,482 | ) | ||||
Accounts payable
|
(3,892,582 | ) | (357,065 | ) | ||||
Accrued expenses
|
634,562 | 427,913 | ||||||
Customer deposits and other
|
(9,150 | ) | (5,251 | ) | ||||
Deferred rent
|
106,657 | (31,732 | ) | |||||
Net cash used in operating activities
|
(2,987,387 | ) | (497,176 | ) | ||||
Cash Flows From Investing Activities
|
||||||||
Purchases of leasehold improvements and equipment
|
(231,201 | ) | (139,162 | ) | ||||
Purchases of intangible assets
|
(195,000 | ) | (22,500 | ) | ||||
Net cash used in investing activities
|
(426,201 | ) | (161,662 | ) | ||||
Cash Flows From Financing Activities
|
||||||||
Proceeds from issuance of common stock, net of issuance costs
|
5,720,000 | - | ||||||
Proceeds from exercise of stock options
|
622,384 | 15,601 | ||||||
Proceeds from loan payable
|
- | 2,500,000 | ||||||
Payment of debt issuance cost
|
- | (15,000 | ) | |||||
Principal payments on loan payable
|
(5,000,000 | ) | - | |||||
Principal payments on capital leases
|
(108,249 | ) | (107,265 | ) | ||||
Net cash provided by financing activities
|
1,234,135 | 2,393,336 | ||||||
Net (decrease) increase in cash
|
(2,179,453 | ) | 1,734,498 | |||||
Cash Beginning of Period
|
5,549,672 | 3,964,750 | ||||||
Cash Ending of Period
|
$ | 3,370,219 | $ | 5,699,248 | ||||
Supplemental Disclosures of Cash Flow Information
|
||||||||
Cash payments for interest
|
$ | 239,839 | $ | 73,202 | ||||
Supplemental Schedule of Noncash Investing Activity
|
||||||||
Capital lease obligation incurred for purchases of equipment
|
$ | - | $ | 303,933 | ||||
Inventory supplied to Healthspan Research, LLC for equity interest, at cost
|
$ | 20,318 | $ | - | ||||
Retirement of fully depreciated equipment - cost
|
$ | 28,083 | $ | - | ||||
Retirement of fully depreciated equipment - accumulated depreciation
|
$ | (28,083 | ) | $ | - |
July 2, 2016
|
January 2, 2016
|
|||||||
Natural product fine chemicals
|
$ | 1,031,287 | $ | 1,239,338 | ||||
Bulk ingredients
|
3,601,516 | 7,195,461 | ||||||
4,632,803 | 8,434,799 | |||||||
Less valuation allowance
|
(108,000 | ) | (261,000 | ) | ||||
$ | 4,524,803 | $ | 8,173,799 |
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
July 2, 2016
|
July 4, 2015
|
July 2, 2016
|
July 4, 2015
|
|||||||||||||
Net income (loss)
|
$ | (82,667 | ) | $ | (315,192 | ) | $ | 172,958 | $ | (1,340,707 | ) | |||||
Basic weighted average common shares outstanding (1):
|
36,990,032 | 35,803,298 | 36,702,037 | 35,768,082 | ||||||||||||
Basic earnings (loss) per common share
|
$ | (0.00 | ) | $ | (0.01 | ) | $ | 0.00 | $ | (0.04 | ) | |||||
Dilutive effect of stock options, net
|
- | - | 726,879 | - | ||||||||||||
Dilutive effect of warrants, net
|
- | - | 41,750 | - | ||||||||||||
Diluted weighted average common shares outstanding :
|
36,990,032 | 35,803,298 | 37,470,666 | 35,768,082 | ||||||||||||
Diluted earnings (loss) per common share
|
$ | (0.00 | ) | $ | (0.01 | ) | $ | 0.00 | $ | (0.04 | ) | |||||
Potentially dilutive securities, total (2):
|
||||||||||||||||
Stock options
|
5,126,943 | 4,706,705 | 4,400,064 | 4,706,705 | ||||||||||||
Warrants
|
487,111 | 156,340 | 445,361 | 156,340 | ||||||||||||
Convertible debt
|
- | 257,798 | - | 257,798 |
Payoff Amount
|
||||
Principal
|
$ | 4,554,659 | ||
Accrued interest
|
15,790 | |||
End of term charge
|
187,500 | |||
Prepayment fee
|
91,093 | |||
Other fees
|
2,500 | |||
Total
|
$ | 4,851,542 |
Net Carrying Amount
|
Payoff Amount (Excluding Interest)
|
||||||||
Principal
|
$ | 4,554,659 |
Principal
|
$ | 4,554,659 | ||||
Accrued end of term charge
|
103,909 |
End of term charge
|
187,500 | ||||||
Deferred financing cost
|
(45,606 | ) |
Prepayment fee
|
91,093 | |||||
Warrant discount
|
(90,309 | ) |
Other fees
|
2,500 | |||||
Total
|
$ | 4,522,653 |
Total
|
$ | 4,835,752 | ||||
(A)
|
(B)
|
||||||||
Loss on debt extinguishment
|
$ | (313,099 | ) | ||||||
(A) - (B)
|
Weighted Average
|
||||||||||||||||||||
Remaining
|
Aggregate
|
|||||||||||||||||||
Number of
|
Exercise
|
Contractual
|
Fair
|
Intrinsic
|
||||||||||||||||
Shares
|
Price
|
Term
|
Value
|
Value
|
||||||||||||||||
Outstanding at January 2, 2016
|
4,314,264 | $ | 3.50 | 6.44 | ||||||||||||||||
Options Granted
|
151,669 | 4.99 | 10.00 | $ | 3.16 | |||||||||||||||
Options Exercised
|
(190,473 | ) | 2.85 | |||||||||||||||||
Options Forfeited
|
(37,699 | ) | 3.49 | |||||||||||||||||
Outstanding at July 2, 2016
|
4,237,761 | $ | 3.58 | 6.04 | $ | 3,150,000 | ||||||||||||||
Exercisable at July 2, 2016
|
3,436,494 | $ | 3.50 | 5.41 | $ | 2,817,082 |
Six Months Ended July 2, 2016
|
||||
Expected term
|
6.1 years
|
|||
Expected volatility
|
73 | % | ||
Expected dividends
|
0.00 | % | ||
Risk-free rate
|
1.50 | % |
March 11, 2016
|
||||
Fair value of common stock
|
$ | 4.41 | ||
Contractual term
|
3.0 years
|
|||
Volatility
|
60.00 | % | ||
Risk-free rate
|
1.16 | % | ||
Expected dividends
|
0.00 | % |
|
·
|
Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients to the manufacturers of consumer products in various industries including the nutritional supplement, food and beverage and animal health industries.
|
|
·
|
Core standards and contract services segment includes supply of phytochemical reference standards, which are small quantities of plant-based compounds typically used to research an array of potential attributes, reference materials and related contract services.
|
|
·
|
Scientific and regulatory consulting segment which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.
|
Three months ended
July 2, 2016 |
Ingredients
segment |
Core Standards and
Contract Services |
Scientific and
Regulatory |
Other
|
Total
|
|||||||||||||||
Net sales
|
$ | 6,241,749 | $ | 2,474,982 | $ | 112,848 | $ | - | $ | 8,829,579 | ||||||||||
Cost of sales
|
3,034,389 | 1,561,287 | 106,456 | - | 4,702,132 | |||||||||||||||
Gross profit
|
3,207,360 | 913,695 | 6,392 | - | 4,127,447 | |||||||||||||||
Operating expenses:
|
||||||||||||||||||||
Sales and marketing
|
399,700 | 294,531 | 3,800 | - | 698,031 | |||||||||||||||
Research and development
|
736,726 | 15,000 | - | - | 751,726 | |||||||||||||||
General and administrative
|
- | - | - | 2,306,559 | 2,306,559 | |||||||||||||||
Operating expenses
|
1,136,426 | 309,531 | 3,800 | 2,306,559 | 3,756,316 | |||||||||||||||
Operating income (loss)
|
$ | 2,070,934 | $ | 604,164 | $ | 2,592 | $ | (2,306,559 | ) | $ | 371,131 |
Three months ended
July 4, 2015 |
Ingredients
segment |
Core Standards and
Contract Services |
Scientific and
Regulatory |
Other
|
Total
|
|||||||||||||||
Net sales
|
$ | 3,411,636 | $ | 2,371,477 | $ | 318,267 | $ | - | $ | 6,101,380 | ||||||||||
Cost of sales
|
1,869,205 | 1,635,294 | 126,189 | - | 3,630,688 | |||||||||||||||
Gross profit
|
1,542,431 | 736,183 | 192,078 | - | 2,470,692 | |||||||||||||||
Operating expenses:
|
||||||||||||||||||||
Sales and marketing
|
298,281 | 336,392 | 5,075 | - | 639,748 | |||||||||||||||
Research and development
|
175,410 | - | - | - | 175,410 | |||||||||||||||
General and administrative
|
- | - | - | 1,839,594 | 1,839,594 | |||||||||||||||
Operating expenses
|
473,691 | 336,392 | 5,075 | 1,839,594 | 2,654,752 | |||||||||||||||
Operating income (loss)
|
$ | 1,068,740 | $ | 399,791 | $ | 187,003 | $ | (1,839,594 | ) | $ | (184,060 | ) |
Six months ended
July 2, 2016 |
Ingredients
segment |
Core Standards and
Contract Services |
Scientific and
Regulatory |
Other
|
Total
|
|||||||||||||||
Net sales
|
$ | 10,842,375 | $ | 5,058,648 | $ | 260,501 | $ | - | $ | 16,161,524 | ||||||||||
Cost of sales
|
5,133,551 | 3,233,271 | 215,836 | - | 8,582,658 | |||||||||||||||
Gross profit
|
5,708,824 | 1,825,377 | 44,665 | - | 7,578,866 | |||||||||||||||
Operating expenses:
|
||||||||||||||||||||
Sales and marketing
|
731,443 | 503,910 | 7,400 | - | 1,242,753 | |||||||||||||||
Research and development
|
1,200,798 | 15,000 | - | - | 1,215,798 | |||||||||||||||
General and administrative
|
- | - | - | 4,295,118 | 4,295,118 | |||||||||||||||
Operating expenses
|
1,932,241 | 518,910 | 7,400 | 4,295,118 | 6,753,669 | |||||||||||||||
Operating income (loss)
|
$ | 3,776,583 | $ | 1,306,467 | $ | 37,265 | $ | (4,295,118 | ) | $ | 825,197 |
Six months ended
July 4, 2015 |
Ingredients
segment |
Core Standards and
Contract Services |
Scientific and
Regulatory |
Other
|
Total
|
|||||||||||||||
Net sales
|
$ | 6,091,977 | $ | 4,671,520 | $ | 598,854 | $ | - | $ | 11,362,351 | ||||||||||
Cost of sales
|
3,472,381 | 3,209,078 | 282,576 | - | 6,964,035 | |||||||||||||||
Gross profit
|
2,619,596 | 1,462,442 | 316,278 | - | 4,398,316 | |||||||||||||||
Operating expenses:
|
||||||||||||||||||||
Sales and marketing
|
572,905 | 647,336 | 5,284 | - | 1,225,525 | |||||||||||||||
Research and development
|
296,505 | - | - | - | 296,505 | |||||||||||||||
General and administrative
|
- | - | - | 3,966,430 | 3,966,430 | |||||||||||||||
Operating expenses
|
869,410 | 647,336 | 5,284 | 3,966,430 | 5,488,460 | |||||||||||||||
Operating income (loss)
|
$ | 1,750,186 | $ | 815,106 | $ | 310,994 | $ | (3,966,430 | ) | $ | (1,090,144 | ) |
At July 2, 2016 |
Ingredients
segment |
Core Standards and
Contract Services |
Scientific and
Regulatory |
Other
|
Total
|
|||||||||||||||
Total assets
|
$ | 10,072,279 | $ | 3,443,044 | $ | 71,512 | $ | 4,192,678 | $ | 17,779,513 |
At January 2, 2016 |
Ingredients
segment |
Core Standards and
Contract Services |
Scientific and
Regulatory |
Other
|
Total
|
|||||||||||||||
Total assets
|
$ | 9,105,502 | $ | 3,306,624 | $ | 111,765 | $ | 6,225,318 | $ | 18,749,209 |
Percentage of the Company's Total Sales
|
||||||||||||||||
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
Major Customers
|
July 2, 2016
|
July 4, 2015
|
July 2, 2016
|
July 4, 2015
|
||||||||||||
Customer C (ingredients segment)
|
34.5 | % | * | 31.3 | % | * | ||||||||||
Customer B (ingredients segment)
|
* | 11.8 | % | * | 10.8 | % |
Three months ending
|
Six months ending
|
|||||||||||||||
July 2, 2016
|
July 4, 2015
|
July 2, 2016
|
July 4, 2015
|
|||||||||||||
Net sales
|
$ | 8,830,000 | $ | 6,101,000 | $ | 16,162,000 | $ | 11,362,000 | ||||||||
Net income (loss)
|
(83,000 | ) | (315,000 | ) | 173,000 | (1,341,000 | ) | |||||||||
Basic earnings (loss) per common share
|
$ | (0.00 | ) | $ | (0.01 | ) | $ | 0.00 | $ | (0.04 | ) | |||||
Diluted earnings (loss) per common share
|
$ | (0.00 | ) | $ | (0.01 | ) | $ | 0.00 | $ | (0.04 | ) |
Three months ending
|
Six months ending
|
|||||||||||||||||||||||
July 2, 2016
|
July 4, 2015
|
Change
|
July 2, 2016
|
July 4, 2015
|
Change
|
|||||||||||||||||||
Net sales:
|
||||||||||||||||||||||||
Ingredients
|
$ | 6,242,000 | $ | 3,412,000 | 83 | % | $ | 10,842,000 | $ | 6,092,000 | 78 | % | ||||||||||||
Core standards and contract services
|
2,475,000 | 2,371,000 | 4 | % | 5,059,000 | 4,671,000 | 8 | % | ||||||||||||||||
Scientific and regulatory consulting
|
113,000 | 318,000 | -64 | % | 261,000 | 599,000 | -56 | % | ||||||||||||||||
Total net sales
|
$ | 8,830,000 | $ | 6,101,000 | 45 | % | $ | 16,162,000 | $ | 11,362,000 | 42 | % |
|
·
|
The increase in sales for the ingredients segment is mainly due to increased sales of “NIAGEN®” and “PTEROPURE®.”
|
|
·
|
The increase in sales for the core standards and contract services segment is primarily due to increased sales of analytical testing and contract services.
|
|
·
|
The decrease in sales for the scientific and regulatory consulting segment is due to the timing of completion of consulting projects for customers and a further emphasis on intercompany work supporting our ingredients segment.
|
Three months ending
|
Six months ending
|
|||||||||||||||||||||||||||||||
July 2, 2016
|
July 4, 2015
|
July 2, 2016
|
July 4, 2015
|
|||||||||||||||||||||||||||||
Amount
|
% of
net sales
|
Amount
|
% of
net sales
|
Amount
|
% of
net sales
|
Amount
|
% of
net sales
|
|||||||||||||||||||||||||
Cost of sales:
|
||||||||||||||||||||||||||||||||
Ingredients
|
$ | 3,035,000 | 49 | % | $ | 1,869,000 | 55 | % | $ | 5,134,000 | 47 | % | $ | 3,472,000 | 57 | % | ||||||||||||||||
Core standards and contract services
|
1,561,000 | 63 | % | 1,636,000 | 69 | % | 3,233,000 | 64 | % | 3,209,000 | 69 | % | ||||||||||||||||||||
Scientific and regulatory consulting
|
106,000 | 94 | % | 126,000 | 40 | % | 216,000 | 83 | % | 283,000 | 47 | % | ||||||||||||||||||||
Total cost of sales
|
$ | 4,702,000 | 53 | % | $ | 3,631,000 | 60 | % | $ | 8,583,000 | 53 | % | $ | 6,964,000 | 61 | % |
|
·
|
The decrease in cost of sales, as a percentage of net sales, for the ingredients segment is largely due to price reductions from our suppliers through increased purchase volumes.
|
|
·
|
The cost of sales, as a percentage of net sales for the core standards and contract services segment, decreased 6% and 5% for the three- and six-month periods ended July 2, 2016, respectively, compared to the comparable periods in 2015. The increase in analytical testing and contract services sales led to a higher labor utilization rate, which resulted in lowering our cost of sales as a percentage of net sales.
|
|
·
|
The percentage increase in cost of sales for the scientific and regulatory consulting segment is largely due to completing less consulting projects and a further emphasis on intercompany work. Fixed labor costs make up the majority of costs for the consulting segment.
|
Three months ending
|
Six months ending
|
|||||||||||||||||||||||
July 2, 2016
|
July 4, 2015
|
Change
|
July 2, 2016
|
July 4, 2015
|
Change
|
|||||||||||||||||||
Gross profit:
|
||||||||||||||||||||||||
Ingredients
|
$ | 3,207,000 | $ | 1,543,000 | 108 | % | $ | 5,709,000 | $ | 2,620,000 | 118 | % | ||||||||||||
Core standards and contract services
|
914,000 | 736,000 | 24 | % | 1,825,000 | 1,462,000 | 25 | % | ||||||||||||||||
Scientific and regulatory consulting
|
6,000 | 192,000 | -97 | % | 45,000 | 316,000 | -86 | % | ||||||||||||||||
Total gross profit
|
$ | 4,127,000 | $ | 2,471,000 | 67 | % | $ | 7,579,000 | $ | 4,398,000 | 72 | % |
|
·
|
The increased gross profits for the ingredients segment is due to the increased sales of the ingredient portfolio we offer, coupled with lower prices from our suppliers due to increased purchase volumes.
|
|
·
|
The increased gross profit for the core standards and contract services segment is largely due to the increased sale of analytical testing and contract services. Fixed labor costs make up the majority of costs for analytical testing and contract services and these fixed labor costs did not increase in proportion to sales, hence yielding higher profit margin.
|
|
·
|
The decreased gross profit for the scientific and regulatory consulting segment is largely due to the decrease in sales and a greater focus on intercompany work supporting our ingredients segment.
|
Three months ending
|
Six months ending
|
|||||||||||||||||||||||
July 2, 2016
|
July 4, 2015
|
Change
|
July 2, 2016
|
July 4, 2015
|
Change
|
|||||||||||||||||||
Sales and marketing expenses:
|
||||||||||||||||||||||||
Ingredients
|
$ | 400,000 | $ | 298,000 | 34 | % | $ | 732,000 | $ | 573,000 | 28 | % | ||||||||||||
Core standards and contract services
|
294,000 | 337,000 | -13 | % | 504,000 | 648,000 | -22 | % | ||||||||||||||||
Scientific and regulatory consulting
|
4,000 | 5,000 | -20 | % | 7,000 | 5,000 | 40 | % | ||||||||||||||||
Total sales and marketing expenses
|
$ | 698,000 | $ | 640,000 | 9 | % | $ | 1,243,000 | $ | 1,226,000 | 1 | % |
|
·
|
For the ingredients segment, the increase is largely due to increased marketing efforts for our line of proprietary ingredients as well as hiring additional marketing staff.
|
|
·
|
For the core standards and contract services segment, the decrease is largely due to making certain operational changes as certain personnel who were previously assigned to sales and marketing group were moved to an administrative group. We do anticipate increased expenses going forward as we increase marketing efforts and hire additional staff.
|
|
·
|
For the scientific and regulatory consulting segment, we had very little sales and marketing expenses.
|
Three months ending
|
Six months ending
|
|||||||||||||||||||||||
July 2, 2016
|
July 4, 2015
|
Change
|
July 2, 2016
|
July 4, 2015
|
Change
|
|||||||||||||||||||
Research and development expenses:
|
||||||||||||||||||||||||
Ingredients
|
$ | 737,000 | $ | 175,000 | 321 | % | $ | 1,201,000 | $ | 297,000 | 304 | % | ||||||||||||
Core standards and contract services
|
15,000 | - | 15,000 | - | ||||||||||||||||||||
Total research and development expenses
|
$ | 752,000 | $ | 175,000 | 330 | % | $ | 1,216,000 | $ | 297,000 | 309 | % |
|
·
|
For the ingredients segment, we increased our research and development efforts with a focus on our “NIAGEN®” brand. Subject to available financial resources, we plan to continue to increase research and development efforts for our line of proprietary ingredients.
|
|
·
|
For the core standards and contract services segment, we explored processes to develop certain compounds at a larger scale during the three months ended July 2, 2016.
|
Three months ending
|
Six months ending
|
|||||||||||||||||||||||
July 2, 2016
|
July 4, 2015
|
Change |
July 2, 2016
|
July 4, 2015
|
Change
|
|||||||||||||||||||
General and administrative
|
$ | 2,307,000 | $ | 1,840,000 | 25 | % | $ | 4,295,000 | $ | 3,966,000 | 8 | % |
|
·
|
One of the factors that contributed to the increase in general and administrative expense was an increase in royalties we pay to patent holders as the sales for licensed products increased in 2016. For the six-month period ended July 2, 2016, royalty expense increased to approximately $446,000, compared to approximately $261,000 for the comparable period in 2015.
|
|
·
|
Another factor that contributed to the increase was an increase in patent maintenance expense. For the six-month period ended July 2, 2016, our patent maintenance expense increased to approximately $343,000, compared to approximately $156,000 for the comparable period in 2015.
|
|
·
|
Another factor that contributed to the increase for the six-month period ended July 2, 2016 was an increase of approximately $254,000 in expenses associated with administrative staff. We made certain operational changes as certain personnel who were previously assigned to our sales and marketing group were moved to an administrative group in 2016.
|
|
·
|
Also, during the three-month period ended July 2, 2016, there were one-time expenses of approximately $89,000 associated with the initial listing of the Company’s stock in the NASDAQ Capital Market.
|
|
·
|
These increases in expenses were offset by the decrease in share-based compensation expense. For the six-month period ended July 2, 2016, our share-based compensation expense decreased to approximately $658,000, compared to approximately $1,223,000 for the comparable period in 2015.
|
Three months ending
|
Six months ending
|
|||||||||||||||||||||||
July 2, 2016
|
July 4, 2015
|
Change
|
July 2, 2016
|
July 4, 2015
|
Change
|
|||||||||||||||||||
Interest expense
|
$ | 145,000 | $ | 132,000 | 10 | % | $ | 334,000 | $ | 252,000 | 33 | % |
|
·
|
The increase in interest expense was mainly related to the Term Loan Agreement dated September 29, 2014, between the Company and Hercules Technology II, L.P, from which the Company drew down an initial $2.5 million on September 29, 2014 and a second $2.5 million on June 18, 2015. The Company fully repaid the loan on June 14, 2016.
|
•
|
the revenues generated by sales of our products;
|
•
|
the costs associated with expanding our sales and marketing efforts, including efforts to hire independent agents and sales representatives and obtain required regulatory approvals and clearances;
|
•
|
the expenses we incur in developing and commercializing our products, including the cost of obtaining and maintaining regulatory approvals; and
|
•
|
unanticipated general and administrative expenses.
|
•
|
our ability to maintain our products at prices that are competitive with those of our competitors;
|
•
|
our ability to maintain quality levels for our products sufficient to meet the expectations of our customers;
|
•
|
our ability to produce, ship and deliver a sufficient quantity of our products in a timely manner to meet the needs of our customers;
|
•
|
our ability to continue to develop and launch new products that our customers feel meet their needs and requirements, with respect to cost, timeliness, features, performance and other factors;
|
•
|
our ability to provide timely, responsive and accurate customer support to our customers; and
|
•
|
the ability of our customers to effectively deliver, market and increase sales of their own products based on ours.
|
•
|
the announcement or introduction of new products by our competitors;
|
•
|
our ability to upgrade and develop our systems and infrastructure to accommodate growth;
|
•
|
our ability to attract and retain key personnel in a timely and cost effective manner;
|
•
|
technical difficulties;
|
•
|
the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure;
|
•
|
regulation by federal, state or local governments; and
|
•
|
general economic conditions as well as economic conditions specific to the healthcare industry.
|
•
|
we may not be able to obtain regulatory approvals for our products, or the approved indication may be narrower than we seek;
|
•
|
our products may not prove to be safe and effective in clinical trials;
|
•
|
we may experience delays in our development program;
|
•
|
any products that are approved may not be accepted in the marketplace;
|
•
|
we may not have adequate financial or other resources to complete the development or to commence the commercialization of our products or will not have adequate financial or other resources to achieve significant commercialization of our products;
|
•
|
we may not be able to manufacture any of our products in commercial quantities or at an acceptable cost;
|
•
|
rapid technological change may make our products obsolete;
|
•
|
we may be unable to effectively protect our intellectual property rights or we may become subject to claims that our activities have infringed the intellectual property rights of others; and
|
•
|
we may be unable to obtain or defend patent rights for our products.
|
|
•
|
our ability to integrate operations, technology, products and services;
|
|
•
|
our ability to execute our business plan;
|
|
•
|
our operating results are below expectations;
|
|
•
|
our issuance of additional securities, including debt or equity or a combination thereof,;
|
|
•
|
announcements of technological innovations or new products by us or our competitors;
|
|
•
|
media coverage regarding our industry or us;
|
|
•
|
loss of any strategic relationship;
|
|
•
|
industry developments, including, without limitation, changes in healthcare policies or practices;
|
|
•
|
economic and other external factors;
|
|
•
|
period-to-period fluctuations in our financial results; and
|
|
•
|
whether an active trading market in our common stock develops and is maintained.
|
•
|
make a special written suitability determination for the purchaser;
|
•
|
receive the purchaser’s written agreement to a transaction prior to sale;
|
•
|
provide the purchaser with risk disclosure documents which identify certain risks associated with investing in “penny stocks” and which describe the market for these “penny stocks” as well as a purchaser’s legal remedies;
|
•
|
obtain a signed and dated acknowledgment from the purchaser demonstrating that the purchaser has received the required risk disclosure document before a transaction in a “penny stock” can be completed; and
|
•
|
give bid and offer quotations and broker and salesperson compensation information to the customer orally or in writing before or with the confirmation.
|
2.1 |
Agreement and Plan of Merger, dated as of May 21, 2008, by and among Cody Resources, Inc., CDI Acquisition, Inc. and ChromaDex, Inc., as amended on June 10, 2008 (incorporated by reference to, and filed as Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 24, 2008)
|
||
3.1 |
Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to, and filed as Appendix A to the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on May 4, 2010)
|
||
3.2 |
Bylaws of the Registrant (incorporated by reference to, and filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 24, 2008)
|
||
3.3 |
Certificate of Amendment to the [Amended and Restated] Certificate of Incorporation of the Registrant (incorporated by reference to, and filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on April 12, 2016)
|
||
3.4 |
Amendment to Bylaws of the Registrant (incorporated by reference to, and filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on July 19, 2016)
|
||
4.1 |
Form of Stock Certificate representing shares of the Registrant’s Common Stock (incorporated by reference to, and filed as Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K filed with the Commission on April 3, 2009)
|
||
4.2 |
Investor’s Rights Agreement, effective as of December 31, 2005, by and between The University of Mississippi Research Foundation and the Registrant (incorporated by reference to, and filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 24, 2008)
|
||
4.3 |
Tag-Along Agreement effective as of December 31, 2005, by and among the Registrant, Frank Louis Jaksch, Snr. & Maria Jaksch, Trustees of the Jaksch Family Trust, Margery Germain, Lauren Germain, Emily Germain, Lucie Germain, Frank Louis Jaksch, Jr., and the University of Mississippi Research Foundation (incorporated by reference to, and filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 24, 2008)
|
||
4.4 |
Form of Stock Certificate representing shares of the Registrant’s Common Stock effective as of January 1, 2016 (incorporated by reference to, and filed as Exhibit 4.4 to the Registrant’s Annual Report on Form 10-K filed with the Commission on March 17, 2016)
|
||
10.1 |
Lease Agreement, made as of April 14, 2016, by and between Longmont Diagonal Investments LLC and ChromaDex Analytics, Inc. (incorporated by reference to, and filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on April 20, 2016)
|
||
10.2 |
Form of Securities Purchase Agreement, entered into by and between the Registrant and certain existing stockholders on June 3, 2016 (incorporated by reference to, and filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 6, 2016)
|
||
31.1 |
Certification of the Chief Executive Officer pursuant to Rule 13a-14(A) of the Securities Exchange Act of 1934, as amended
|
||
31.2 |
Certification of the Chief Financial Officer pursuant to Rule 13a-14(A) of the Securities Exchange Act of 1934, as amended
|
||
32.1 |
Certification pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002)
|
||
101.INS
|
XBRL Instance Document
|
||
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
||
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
||
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
||
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
||
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
CHROMADEX CORPORATION | ||
Date: August 11, 2016 | /s/ THOMAS C. VARVARO | |
Thomas C. Varvaro | ||
Chief Financial Officer | ||
(principal financial and accounting officer and duly
authorized on behalf of the registrant)
|
Document and Entity Information - shares |
6 Months Ended | |
---|---|---|
Jul. 02, 2016 |
Aug. 10, 2016 |
|
Document And Entity Information | ||
Entity Registrant Name | ChromaDex Corp. | |
Entity Central Index Key | 0001386570 | |
Document Type | 10-Q | |
Document Period End Date | Jul. 02, 2016 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Is Entity a Well-known Seasoned Issuer? | No | |
Is Entity a Voluntary Filer? | No | |
Is Entity's Reporting Status Current? | Yes | |
Entity Filer Category | Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 37,856,584 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2016 |
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) |
Jul. 02, 2016 |
Jan. 02, 2016 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Allowance for doubtful accounts and returns | $ 397,000 | $ 367,000 |
Common Stock, Par Value Per Share | $ 0.001 | $ .001 |
Common Stock, Shares Authorized | 50,000,000 | 50,000,000 |
Common Stock, Shares, Issued | 37,489,914 | 36,003,589 |
Common Stock, Shares, Outstanding | 37,489,914 | 36,003,589 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jul. 02, 2016 |
Jul. 04, 2015 |
Jul. 02, 2016 |
Jul. 04, 2015 |
|
Income Statement [Abstract] | ||||
Sales, net | $ 8,829,579 | $ 6,101,380 | $ 16,161,524 | $ 11,362,351 |
Cost of sales | 4,702,132 | 3,630,688 | 8,582,658 | 6,964,035 |
Gross profit | 4,127,447 | 2,470,692 | 7,578,866 | 4,398,316 |
Operating expenses: | ||||
Sales and marketing | 698,031 | 639,748 | 1,242,753 | 1,225,525 |
Research and development | 751,726 | 175,410 | 1,215,798 | 296,505 |
General and administrative | 2,306,559 | 1,839,594 | 4,295,118 | 3,966,430 |
Operating expenses | 3,756,316 | 2,654,752 | 6,753,669 | 5,488,460 |
Operating income (loss) | 371,131 | (184,060) | 825,197 | (1,090,144) |
Nonoperating income (expense): | ||||
Interest income | 638 | 645 | 1,432 | 1,363 |
Interest expense | (145,424) | (131,777) | (333,919) | (251,926) |
Loss on debt extinguishment | (313,099) | (313,099) | ||
Nonoperating expenses | (457,885) | (131,132) | (645,586) | (250,563) |
Income (loss) before taxes | (86,754) | (315,192) | 179,611 | (1,340,707) |
Provision for taxes | 4,087 | (6,653) | ||
Net income (loss) | $ (82,667) | $ (315,192) | $ 172,958 | $ (1,340,707) |
Basic earnings (loss) per common share | $ 0.00 | $ (0.01) | $ 0.00 | $ (0.04) |
Diluted earnings (loss) per common share | $ 0.00 | $ (0.01) | $ 0.00 | $ (0.04) |
Basic weighted average common shares outstanding | 36,990,032 | 35,803,298 | 36,702,037 | 35,768,082 |
Diluted weighted average common shares outstanding | 36,990,032 | 35,803,298 | 37,470,666 | 35,768,082 |
Condensed Consolidated Statement of Stockholders' Equity (Parenthetical) - USD ($) |
3 Months Ended | |
---|---|---|
Jul. 02, 2016 |
Apr. 02, 2016 |
|
Statement of Stockholders' Equity [Abstract] | ||
Net offering costs | $ 10,000 | $ 20,000 |
Interim Financial Statements |
6 Months Ended |
---|---|
Jul. 02, 2016 | |
Interim Financial Statements | |
Interim Financial Statements | The accompanying financial statements of ChromaDex Corporation (the Company) and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. include all adjustments, consisting of normal recurring adjustments and accruals, that, in the opinion of the management of the Company, are necessary for a fair presentation of the Companysfinancial position as of July 2, 2016 and results of operations and cash flows for the threeand six months ended July 2, 2016 and July 4, 2015. These unaudited interim financial statements should be read in conjunction with the Companys audited financial statements and the notes thereto for the year ended January 2, 2016 appearing in the Companys Annual Report on Form 10-K filed with the Securities and Exchange Commission (the Commission) on March 17, 2016. Operating results for the sixmonths ended July 2, 2016are not necessarily indicative of the results to be achieved for the full year ending on December 31, 2016. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
The balance sheet at January 2, 2016 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. |
Nature of Business and Liquidity |
6 Months Ended |
---|---|
Jul. 02, 2016 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of Business and Liquidity | Nature of business: The Company leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, Intellectual Property-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive Intellectual Property protection . Liquidity: The Company generatedincome from operations of approximately $825,000and net income of approximately $173,000for the six-month period ended July 2, 2016. As of July 2, 2016, the cash and cash equivalents totaled approximately $3,370,000.
While we anticipate that our current cash, cash equivalents and cash to be generated from operations will be sufficient to meet our projected operating plans through at least August 12, 2017, we may require additional funds, either through additional equity or debt financings or collaborative agreements or from other sources. We have no commitments to obtain such additional financing, and we may not be able to obtain any such additional financing on terms favorable to us, or at all. If adequate financing is not available, the Company will further delay, postpone or terminate product and service expansion and curtail certain selling, general and administrative operations. The inability to raise additional financing may have a material adverse effect on the future performance of the Company. |
Significant Accounting Policies |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Significant Accounting Policies | Basis of presentation: The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Companys fiscal year ends on the Saturday closest to December 31. Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Companys floating year-end date. The fiscal year 2015ended on January 2, 2016 consisted of normal 52 weeks. The fiscal year 2016 ending on December 31, 2016 will also include the normal 52 weeks.
Inventories: Inventories are comprised of raw materials, work-in-processand finished goods. They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market. Labor and overhead has been added to inventory that was manufactured or characterized by the Company. The amounts of major classes of inventory as ofJuly 2, 2016 and January 2, 2016 are as follows:
|
Reverse Stock Split |
6 Months Ended |
---|---|
Jul. 02, 2016 | |
Stockholders' Equity Note [Abstract] | |
Reverse Stock Split | On April 13, 2016, the Company effected a 1-for-3 reverse stock split. All information presented herein has been retrospectively adjusted to reflect the reverse stock split as if they took place as of the earliest period presented. An additional 1,632 shares were issued to round up fractional shares as a result of the reverse stock split. |
Earnings Per Share Applicable to Common Stockholders |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss Per Share Applicable To Common Stockholders | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share Applicable to Common Stockholders | The following table sets forth the computations of earnings per share amounts applicable to common stockholders for the three and six months ended July 2, 2016 and July 4, 2015:
|
Loan Payable |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loan Payable | On June 14, 2016, the Company repaid $4,851,542 owed to Hercules Funding II LLC (Hercules), under the Companys loan and security agreement with Hercules dated as of September 29, 2014 (the Loan Agreement).
The payoff amount was comprised of the following:
Upon Hercules receipt of the Payoff Amount, the Loan Agreement terminated.
The Loan Agreement initially provided the Company with access to a term loan of up to $5 million. The first $2.5 million of the term loan was funded at the closing of the Loan Agreement, and was repayable in installments over 30 months, following an initial interest-only period of twelve months after closing. The Company drew down the remaining $2.5 million of the term loan on June 17, 2015 and the interest-only period was extended to March 31, 2016. In connection with the loan, the Company paid an aggregate of $65,000 in facility charges to Hercules and granted Hercules first priority liens and a security interest in substantially all of its assets.
The Loan Agreement also provided (i) a borrower option to repay principal in common stock up to an aggregate amount of $500,000 at a conversion price of $3.879 per share and (ii) a lender option to receive principal repayments in common stock up to an aggregate amount of $500,000 at a conversion price of $3.879 per share, subject to certain conditions. However, no principal was repaid in common stock. On the commitment date, no separate accounting was required for the conversion feature.
In connection with the termination of the Loan Agreement, Herculess commitments to extend further credit to the Company terminated, all obligations, covenants, debts and liabilities of the Company under the Loan Agreement were satisfied and discharged in full, all documents entered into in connection with the Loan Agreement, other than a warrant issued pursuant to the Loan Agreement, were terminated, all liens or security interests granted to secure the obligations under the Loan Agreement terminated and all guaranties of the Companys obligations under the Loan Agreement terminated.
The payoff amount, excluding the accrued interest to date, was $4,835,752 and the net carrying amount of the debt on the extinguishment date was $4,522,653. The difference of $313,099 was recognized as a non-operating loss in the statement of operations during the three months ended July 2, 2016.
|
Employee Share-Based Compensation |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Employee Share-Based Compensation | Service Period Based Stock Options
The following table summarizes activity of service period based stock options granted to employees at July 2, 2016 and changes during the six months then ended:
The aggregate intrinsic values in the table above are based on the Companys stock price of $4.11, which is the closing price of the Companys stock on the last day of business for the period ended July 2, 2016. The aggregate intrinsic values for options exercised during the six months ended July 2, 2016 was approximately $433,000.
The fair value of the Companys stock options was estimated at the date of grant using the Black-Scholes option pricing model. The table below outlines the weighted average assumptions for options granted to employees during the six months ended July 2, 2016.
As of July 2,2016, there was approximately $1,594,000 of total unrecognized compensation expense under the plans for all employee stock options. That cost is expected to be recognized over a weighted average period of 2.70 years.
Employee Share-Based Compensation
The Company recognized compensation expense of approximately $314,000and $621,000 in general and administrative expenses in the statement of operations for the three and six months ended July 2, 2016, respectively, and approximately $442,000and $820,000 for the three and six months ended July 4, 2015, respectively. |
Stock Issuance |
6 Months Ended | ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2016 | |||||||||||||||||||||||||||||||
Stock Issuance | |||||||||||||||||||||||||||||||
Stock Issuance | On March 11, 2016, the Company entered into a Securities Purchase Agreement (SPA) to raise $500,000 in a registered direct offering. Pursuant to the SPA, the Company sold a total of 128,205 Units at a purchase price of $3.90 per Unit, with each Unit consisting of one share of the Companys common stock and a warrant to purchase one half of a share of common stock (64,103 total) with an exercise price of $4.80 and a term of 3 years. The estimated fair value of the warrant was approximately $108,000 and the warrant was determined to be classified as equity. The fair value was estimated at the date of issuance using the Black-Scholes based valuation model. The table below outlines the assumptions for the warrant issued.
On June 3, 2016, the Company entered into additional SPAs to raise $5,250,000 in a registered direct offering. Pursuant to the SPAs, the Company sold a total of 1,117,022 shares of the Companys common stock at a purchase price of $4.70 per share. |
Business Segments |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Segments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Segments | The Company has the following three reportable segments:
The Other classification includes corporate items not allocated by the Company to each reportable segment. Further, there are no intersegmentsales that require elimination. The Company evaluates performance and allocates resources based on reviewing gross margin by reportable segment.
Disclosure of major customers
Major customers who accounted for more than 10% of the Companys total sales were as follows:
|
Related Party Transactions |
6 Months Ended |
---|---|
Jul. 02, 2016 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | On August 28, 2015, the Company entered into an Exclusive Supply Agreement (the Supply Agreement) with Healthspan Research, LLC (Healthspan). Under the terms of the Supply Agreement, Healthspan agreed to purchase NIAGEN® from the Company and the Company granted to Healthspan worldwide rights for resale of specific dietary supplements containing NIAGEN® in certain direct response channels.
Pursuant to the terms of the Supply Agreement, in exchange for a 4% equity interest in Healthspan, the Company agreed to initially supply NIAGEN® to Healthspan free of charge up to a certain amount on a buy-one-get-one-free basis and thereafter at a fixed price and, in exchange for an additional 5% equity interest in Healthspan, the Company will grant to Healthspan certain exclusive rights to resell NIAGEN®. Healthspan will pay the Company royalties on the cumulative worldwide net sales of its finished products containing NIAGEN®. The exclusivity rights will remain for so long as Healthspan meets certain minimum purchase requirements. In the event that, during the initial term, the Company terminates the exclusivity rights due to failure to meet the minimum purchase requirements or for any reason other than a material breach of the Supply Agreement by Healthspan, then the 5% equity interest shall be automatically redeemed for a purchase price of $1.00 effective upon the date of termination of the exclusivity rights.
In connection with the foregoing, also on August 28, 2015, the Company and Healthspan entered into an interest purchase agreement and limited liability company agreement pursuant to which the Company was issued 9% of the outstanding equity interests of Healthspan. Rob Fried, a director of the Company, is the manager of Healthspan and owns 91% of the outstanding equity interests of Healthspan. The Supply Agreement, interest purchase agreement and limited liability company agreement were unanimously approved by the independent directors of the Company.
During the six months endedJuly 2, 2016, the Company shipped NIAGEN® to Healthspanon a buy-one-get-one-free basis. Our cost of NIAGEN® supplied free of charge was approximately $20,000 and this was recorded as a long-term investment at our cost.
The Company accounts for its ownership interest under the cost method of accounting as the Company does not have an ability to exercise significant influence on Healthspan. |
Commitments and Contingencies |
6 Months Ended |
---|---|
Jul. 02, 2016 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | On February29, 2016, the Company entered into a lease amendment to extend the term of the lease for its laboratory facility located in Boulder, Colorado through April 2023. Pursuant to the lease amendment, the Company will make monthly lease payments ranging from $23,472 to $27,210, as the payments escalate during the term of the lease.
On March 4, 2016, the Company entered into a lease amendment to lease an office space located in Rockville, Maryland through April 2021. Pursuant to the lease amendment, the Company will make monthly lease payments ranging from $3,450 to $3,883, as the payments escalate during the term of the lease.
On April 14, 2016, the Company entered into a lease to lease an office and laboratory space located in Longmont, Colorado through September 2023. Pursuant to the lease, the Company will make monthly lease payments ranging from $8,586 to $11,518, as payments escalate during the term of the lease. Subsequent to the period ended July 2, 2016, the Company agreed to pay additional lease payments of approximately $800 per month as the landlord will provide additional improvements to the leased premises. |
Significant Accounting Policies (Policy) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basis of presentation | Basis of presentation: The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Companys fiscal year ends on the Saturday closest to December 31. Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Companys floating year-end date. The fiscal year 2015ended on January 2, 2016 consisted of normal 52 weeks. The fiscal year 2016 ending on December 31, 2016 will also include the normal 52 weeks. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | Inventories: Inventories are comprised of raw materials, work-in-processand finished goods. They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market. Labor and overhead has been added to inventory that was manufactured or characterized by the Company. The amounts of major classes of inventory as ofJuly 2, 2016 and January 2, 2016 are as follows:
|
Significant Accounting Policies (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories |
|
Earnings Per Share Applicable to Common Stockholders (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss Per Share Applicable To Common Stockholders Tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss per share amounts applicable to common stockholders |
|
Loan Payable (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loan payable | The payoff amount was comprised of following:
|
Employee Share-Based Compensation (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Tables | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Service Period Based Stock Options |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Weighted average assumptions of stock options granted |
|
Stock Issuance (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2016 | |||||||||||||||||||||||||||||||
Stock Issuance | |||||||||||||||||||||||||||||||
Outlines the assumptions for warrant issued |
|
Business Segments (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Segments Tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Segmentation |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Percentage of Sales Table |
|
Nature of Business and Liquidity (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | ||||
---|---|---|---|---|---|---|
Jul. 02, 2016 |
Apr. 02, 2016 |
Jul. 04, 2015 |
Jul. 02, 2016 |
Jul. 04, 2015 |
Jan. 02, 2016 |
|
Liquidity | ||||||
Operating income (loss) | $ 371,131 | $ (184,060) | $ 825,197 | $ (1,090,144) | ||
Net (loss) | (82,667) | $ 255,625 | (315,192) | 172,958 | (1,340,707) | |
Cash and cash equivalents | $ 3,370,219 | $ 5,699,248 | $ 3,370,219 | $ 5,699,248 | $ 5,549,672 |
Significant Accounting Policies (Details) - USD ($) |
Jul. 02, 2016 |
Jan. 02, 2016 |
---|---|---|
Inventories | ||
Natural product fine chemicals | $ 1,031,287 | $ 1,239,338 |
Bulk ingredients | 3,601,516 | 7,195,461 |
Inventory-gross | 4,632,803 | 8,434,799 |
Less valuation allowance | (108,000) | (261,000) |
Inventory-net | $ 4,524,803 | $ 8,173,799 |
Reverse Stock Split (Details Narrative) |
Apr. 13, 2016
shares
|
---|---|
Reverse Stock Split Details Narrative | |
Reverse stock split | 1 for 3 reverse stock split |
Reverse stock split, Share Issued | 1,632 |
Earnings Per Share Applicable to Common Stockholders (Details) (Details Narrative) - shares |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jul. 02, 2016 |
Jul. 04, 2015 |
Jul. 02, 2016 |
Jul. 04, 2015 |
|
Loss Per Share Applicable To Common Stockholders Details Narrative | ||||
Weighted average nonvested shares of restricted stock | 369,220 | 410,161 | 370,923 | 464,095 |
Loan Payable (Details) |
Jul. 02, 2016
USD ($)
|
---|---|
Debt Disclosure [Abstract] | |
Principal, payoff amount | $ 4,554,659 |
Accrued interest, payoff amount | 15,790 |
End of term charge, payoff amount | 187,500 |
Prepayment fee, payoff amount | 91,093 |
Other fees, payoff amount | 2,500 |
Total payoff amount | $ 4,851,542 |
Loan Payable (Details 1) |
Jul. 02, 2016
USD ($)
|
---|---|
Debt Disclosure [Abstract] | |
Principal, carrying amount | $ 4,554,659 |
Accrued end of term charge, carrying amount | 103,909 |
Deferred financing cost, carrying amount | (45,606) |
Warrant discount, carrying amount | (90,309) |
Total carrying amount | 4,522,653 |
Principal, payoff amount | 4,554,659 |
End of term charge, payoff amount | 187,500 |
Prepayment fee, payoff amount | 91,093 |
Other fees, payoff amount | 2,500 |
Total payoff amount | 4,835,752 |
Loss on debt extinguishment | $ (313,099) |
Loan Payable (Details Narrative) - USD ($) |
3 Months Ended | 8 Months Ended | ||
---|---|---|---|---|
Jul. 02, 2016 |
Sep. 14, 2014 |
Jun. 17, 2015 |
Sep. 01, 2014 |
|
Debt Disclosure [Abstract] | ||||
Principal, payoff amount | $ 4,554,659 | |||
Total payoff amount | 4,851,542 | |||
Loan agreement | $ 5,000,000 | |||
Draw down amount | $ 2,500,000 | $ 2,500,000 | ||
Facility fees | 65,000 | |||
Conversion feature | (i) a borrower option to repay principal in common stock up to an aggregate amount of $500,000 at a conversion price of $3.879 per share and (ii) a lender option to receive principal repayments in common stock up to an aggregate amount of $500,000 at a conversion price of $3.879 per share, subject to certain conditions | |||
Total carrying amount | 4,522,653 | |||
Loss on debt extinguishment | $ (313,099) |
Employee Share-Based Compensation (Details 1) |
6 Months Ended | |
---|---|---|
Mar. 11, 2016 |
Jul. 02, 2016 |
|
Employee Share-based Compensation Details 1 | ||
Expected term | 3 years | 6 years 1 month 6 days |
Expected volatility | 60.00% | 73.00% |
Expected dividends | 0.00% | 0.00% |
Risk-free rate | 1.16% | 1.50% |
Employee Share-Based Compensation (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jul. 02, 2016 |
Jul. 04, 2015 |
Jul. 02, 2016 |
Jul. 04, 2015 |
|
Employee Share-based Compensation Details Narrative | ||||
Closing stock price | $ 4.11 | $ 4.11 | ||
Aggregate intrinsic values for options exercised | $ 433,000 | |||
Unrecognized compensation expense | $ 1,594,000 | $ 1,594,000 | ||
Cost is expected to be recognized over a weighted average period | 2 years 8 months 12 days | |||
Recognized compensation expense | $ 314,000 | $ 442,000 | $ 621,000 | $ 820,000 |
Stock Issuance (Details) - $ / shares |
6 Months Ended | |
---|---|---|
Mar. 11, 2016 |
Jul. 02, 2016 |
|
Stock Issuance Details | ||
Fair value of common stock | $ 4.41 | |
Contractual term | 3 years | 6 years 1 month 6 days |
Volatility | 60.00% | 73.00% |
Risk-free rate | 1.16% | 1.50% |
Expected dividends | 0.00% | 0.00% |
Stock Issuance (Details Narrative)) - USD ($) |
Jun. 03, 2016 |
Mar. 11, 2016 |
---|---|---|
Stock Issuance | ||
Proceeds from sale of common stock | $ 5,250,000 | $ 500,000 |
Sale of common stock | 1,117,022 | 128,205 |
Purchase price per unit sold | $ 4.70 | $ 3.90 |
Unit description | of one share of the Companys common stock and a warrant to purchase one half of a share of common stock (64,103 total) with an exercise price of $4.80 and a term of 3 years | |
Unit warrant exercise price | $ 4.80 | |
Unit warrant term | 3 years | |
Fair value of warrants | $ 108,000 |
Business Segments (Details) - USD ($) |
3 Months Ended | 6 Months Ended | |||
---|---|---|---|---|---|
Jul. 02, 2016 |
Jul. 04, 2015 |
Jul. 02, 2016 |
Jul. 04, 2015 |
Jan. 02, 2016 |
|
Business Segmentation | |||||
Net sales | $ 8,829,579 | $ 6,101,380 | $ 16,161,524 | $ 11,362,351 | |
Cost of sales | 4,702,132 | 3,630,688 | 8,582,658 | 6,964,035 | |
Gross profit | 4,127,447 | 2,470,692 | 7,578,866 | 4,398,316 | |
Operating expenses: | |||||
Sales and marketing | 698,031 | 639,748 | 1,242,753 | 1,225,525 | |
Research and development | 751,726 | 175,410 | 1,215,798 | 296,505 | |
General and administrative | 2,306,559 | 1,839,594 | 4,295,118 | 3,966,430 | |
Operating expenses | 3,756,316 | 2,654,752 | 6,753,669 | 5,488,460 | |
Operating income (loss) | 371,131 | (184,060) | 825,197 | (1,090,144) | |
Total assets | 17,779,513 | 17,779,513 | $ 18,749,209 | ||
Ingredients Segment [Member] | |||||
Business Segmentation | |||||
Net sales | 6,241,749 | 3,411,636 | 10,842,375 | 6,091,977 | |
Cost of sales | 3,034,389 | 1,869,205 | 5,133,551 | 3,472,381 | |
Gross profit | 3,207,360 | 1,542,431 | 5,708,824 | 2,619,596 | |
Operating expenses: | |||||
Sales and marketing | 399,700 | 298,281 | 731,443 | 572,905 | |
Research and development | 736,726 | 175,410 | 1,200,798 | 296,505 | |
General and administrative | |||||
Operating expenses | 1,136,426 | 473,691 | 1,932,241 | 869,410 | |
Operating income (loss) | 2,070,934 | 1,068,740 | 3,776,583 | 1,750,186 | |
Total assets | 10,072,279 | 10,072,279 | 9,105,502 | ||
Core Standards and Contract Services Segment [Member] | |||||
Business Segmentation | |||||
Net sales | 2,474,982 | 2,371,477 | 5,058,648 | 4,671,520 | |
Cost of sales | 1,561,287 | 1,635,294 | 3,233,271 | 3,209,078 | |
Gross profit | 913,695 | 736,183 | 1,825,377 | 1,462,442 | |
Operating expenses: | |||||
Sales and marketing | 294,531 | 336,392 | 503,910 | 647,336 | |
Research and development | 15,000 | 15,000 | |||
General and administrative | |||||
Operating expenses | 309,531 | 336,392 | 518,910 | 647,336 | |
Operating income (loss) | 604,164 | 399,791 | 1,306,467 | 815,106 | |
Total assets | 3,443,044 | 3,443,044 | 3,306,624 | ||
Scientific and Regulatory Consulting Segment [Member] | |||||
Business Segmentation | |||||
Net sales | 112,848 | 318,267 | 260,501 | 598,854 | |
Cost of sales | 106,456 | 126,189 | 215,836 | 282,576 | |
Gross profit | 6,392 | 192,078 | 44,665 | 316,278 | |
Operating expenses: | |||||
Sales and marketing | 3,800 | 5,075 | 7,400 | 5,284 | |
Research and development | |||||
General and administrative | |||||
Operating expenses | 3,800 | 5,075 | 7,400 | 5,284 | |
Operating income (loss) | 2,592 | 187,003 | 37,265 | 310,994 | |
Total assets | 71,512 | 71,512 | 111,765 | ||
Other Segment [Member] | |||||
Business Segmentation | |||||
Net sales | |||||
Cost of sales | |||||
Gross profit | |||||
Operating expenses: | |||||
Sales and marketing | |||||
Research and development | |||||
General and administrative | 2,306,559 | 1,839,594 | 4,295,118 | 3,966,430 | |
Operating expenses | 2,306,559 | 1,839,594 | 4,295,118 | 3,966,430 | |
Operating income (loss) | (2,306,559) | $ (1,839,594) | (4,295,118) | $ (3,966,430) | |
Total assets | $ 4,192,678 | $ 4,192,678 | $ 6,225,318 |
Business Segments (Details 1) - Ingredients Segment [Member] |
3 Months Ended | 6 Months Ended | |||
---|---|---|---|---|---|
Jul. 02, 2016 |
Jul. 04, 2015 |
Jul. 02, 2015 |
Jul. 02, 2016 |
Jul. 04, 2015 |
|
Customer C [Member] | |||||
Customer concentration risk | 34.50% | 31.30% | |||
Customer B [Member] | |||||
Customer concentration risk | 11.80% | 10.80% |
Related Party Transactions (Details Narrative) - Related Party [Member] |
6 Months Ended |
---|---|
Jul. 02, 2016
USD ($)
| |
Related party transaction description | Pursuant to the terms of the Supply Agreement, in exchange for a 4% equity interest in Healthspan, the Company agreed to initially supply NIAGEN® to Healthspan free of charge and thereafter at a fixed price and, in exchange for an additional 5% equity interest in Healthspan, the Company will grant to Healthspan certain exclusive rights to resell NIAGEN® in certain direct response channels. Healthspan will pay the Company royalties on the cumulative worldwide net sales of its finished products containing NIAGEN®. The exclusivity rights will remain for so long as Healthspan meets certain minimum purchase requirements. |
Equity interest received | 5.00% |
Supply charges recorded as long term investment | $ 20,000 |
Commitments and Contingencies (Details Narrative) - Lease Purchase Commitment [Member] - USD ($) |
Apr. 14, 2016 |
Mar. 04, 2016 |
Feb. 29, 2016 |
---|---|---|---|
Minimum [Member] | |||
Monthly lease payment | $ 8,586 | $ 3,450 | $ 23,472 |
Additional monthly payment | 800 | ||
Maximum [Member] | |||
Monthly lease payment | 11,518 | $ 3,883 | $ 27,210 |
Additional monthly payment | $ 800 |
O7 <+,
M".;5OVV1G[?8Y2?T_'?Z\L+A,M*7D\.;WP56%P*K*+#Z<<1SS.U%$W:RIPI,
M&Z^.)14.VJ7-FZOS[;S+XYE\P .!T_G^'0>@>!8
M>-9QJ6B$RYF1G!&_7/I%C\2# *"E1#$J&:40!NE C"Q^_"_\;^Y%]F*^A)^F
M;G=Q@<7)G1Z!:\]#I^GPH(0T&T7*W [F#NQ)I"/EV$S[<6AY ^(2U!4Y2FNU
MUK+Q/$$Z4A74J7?VQ+K2\<6 /@!-R\ 'HIH[N'\A_ JP/BP*VF?6+Q)=+%B
M(G%=YH814A$+@M#VH^9OC*4 JBH*1I.!!GCUPCEHAX7VTP(JPE +FOB@I**E
M[7FBYC1P'=N%\0:8SW**[&',1R)_,TC$]GCU>![M5K@*V\Z'75MZOH J"FQG
M&1X#53$.UAB"L\D!:9!0(FA
MF8ONC2+HV<"ZH/K.-^;@^S.DO386_5#S#2R,?Z[!Y'(#DX$ARYI/P *P;H*
M/"N_4Z'?8E5CY.)Y+<3"BQ<4^3W]^)MZ]?%/9S:#M[SH1Y4HF2",<=K2^]:#
M$0&E9G1*L%K"AKC"N @%8KPE 1NHX"GAYT(- ?/*"$U\GV\V4@."("QIXXL$
M[WW,(]RA=1N\Z;S2BIH>=$\X_H%IA.L@6*&T\4NJP3I4
M1PHEBK^G5>BXCNG/
R!(89+%B8H3GG'T]N&O>--
MA8I)0$2+LA0OK M^Q]9X$$58EGB6">>87FZN^&NNF%\*"R,\N$[^H1(R Q!,
MD5&KC3N^H'ABQGLA8IRIR[C$MLAD-X#(&QEQ.XE"W%B?T<5+*H*\IZM=-E![52A(8H*$>KML!X>
M!!05B